Jay Visaria

411 total citations
23 papers, 291 citations indexed

About

Jay Visaria is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Economics and Econometrics. According to data from OpenAlex, Jay Visaria has authored 23 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Epidemiology and 5 papers in Economics and Econometrics. Recurrent topics in Jay Visaria's work include Diabetes Treatment and Management (5 papers), Pharmaceutical Economics and Policy (5 papers) and Medical Device Sterilization and Disinfection (3 papers). Jay Visaria is often cited by papers focused on Diabetes Treatment and Management (5 papers), Pharmaceutical Economics and Policy (5 papers) and Medical Device Sterilization and Disinfection (3 papers). Jay Visaria collaborates with scholars based in United States and United Kingdom. Jay Visaria's co-authors include Rosa Rodríguez-Monguió, Enrique Seoane‐Vazquez, Sheryl L. Szeinbach, Vincent J. Willey, Angeline M. Carlson, Rochelle Henderson, David M. Kern, Joseph Singer, Amit D. Raval and Tao Gu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Diabetes.

In The Last Decade

Jay Visaria

21 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay Visaria United States 10 89 65 60 42 38 23 291
Aliya Jiwani United States 9 40 0.4× 53 0.8× 26 0.4× 69 1.6× 38 1.0× 13 536
Amanda M. Farr United States 12 46 0.5× 66 1.0× 3 0.1× 29 0.7× 37 1.0× 36 441
L. Lévy-Bachelot France 11 43 0.5× 36 0.6× 5 0.1× 31 0.7× 24 0.6× 49 393
Sohee Park South Korea 9 24 0.3× 60 0.9× 4 0.1× 15 0.4× 49 1.3× 31 260
Caterina Bianca Neve Aurora Bianchi Italy 10 42 0.5× 23 0.4× 7 0.1× 40 1.0× 61 1.6× 12 483
Anthony S. Gunnell Australia 10 22 0.2× 17 0.3× 14 0.2× 32 0.8× 59 1.6× 14 378
Kari S. Lankinen Finland 11 23 0.3× 147 2.3× 177 3.0× 62 1.5× 39 1.0× 15 619
A. Cohen United States 9 13 0.1× 18 0.3× 41 0.7× 65 1.5× 29 0.8× 12 351
Vasileios Sioulas Greece 11 17 0.2× 21 0.3× 6 0.1× 68 1.6× 45 1.2× 26 413
Marleen E. Jansen Netherlands 10 40 0.4× 10 0.2× 5 0.1× 67 1.6× 32 0.8× 21 309

Countries citing papers authored by Jay Visaria

Since Specialization
Citations

This map shows the geographic impact of Jay Visaria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Visaria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Visaria more than expected).

Fields of papers citing papers by Jay Visaria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Visaria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Visaria. The network helps show where Jay Visaria may publish in the future.

Co-authorship network of co-authors of Jay Visaria

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Visaria. A scholar is included among the top collaborators of Jay Visaria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Visaria. Jay Visaria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Visaria, Jay, et al.. (2021). Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population. Clinical Therapeutics. 43(5). 808–821. 18 indexed citations
3.
Visaria, Jay, et al.. (2020). Healthcare Costs of Diabetes and Microvascular and Macrovascular Disease in Individuals with Incident Type 2 Diabetes Mellitus: A Ten-Year Longitudinal Study. SHILAP Revista de lepidopterología. 1 indexed citations
4.
Bauer, Karri A., Kelly Johnson, Judith J. Stephenson, et al.. (2020). Rate of preventative vaccine use and vaccine beliefs among a commercially insured population. Vaccine. 38(45). 7087–7093. 3 indexed citations
5.
Visaria, Jay, Neeraj N. Iyer, Amit D. Raval, et al.. (2020). <p>Healthcare Costs of Diabetes and Microvascular and Macrovascular Disease in Individuals with Incident Type 2 Diabetes Mellitus: A Ten-Year Longitudinal Study</p>. ClinicoEconomics and Outcomes Research. Volume 12. 423–434. 20 indexed citations
6.
Pemmaraju, Naveen, Jingbo Yu, Shreekant Parasuraman, et al.. (2020). Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.. Journal of Clinical Oncology. 38(15_suppl). e19535–e19535. 4 indexed citations
7.
8.
Visaria, Jay, Nina Thomas, Tao Gu, Joseph Singer, & Hiangkiat Tan. (2018). Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. Clinical Therapeutics. 40(6). 926–939. 9 indexed citations
9.
Deshpande, Gaurav, Jay Visaria, Joseph Singer, & Kelly Johnson. (2018). Impact of medical and/or pharmacy reimbursement on adult vaccination rates.. PubMed. 24(8 Spec No.). SP286–SP293. 4 indexed citations
10.
Visaria, Jay, et al.. (2016). Real-World Treatment Persistence with Vedolizumab in Patients with Ulcerative Colitis and Crohnʼs Disease: A Retrospective Claims Analysis in the U.S.. The American Journal of Gastroenterology. 111. S322–S324. 1 indexed citations
11.
Henderson, Rochelle, et al.. (2014). Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence. Journal of Managed Care Pharmacy. 20(12). 1227–1234. 13 indexed citations
12.
Henderson, Rochelle, et al.. (2013). Dispensing channel and medication adherence: evidence across 3 therapy classes.. PubMed. 19(10). 798–804. 18 indexed citations
13.
Visaria, Jay, et al.. (2009). PMC83 USE OF CONJOINT ANALYSIS IN HEALTH OUTCOMES RESEARCH: AN EXAMINATION OF THE LITERATURE. Value in Health. 12(3). A34–A34. 2 indexed citations
14.
Visaria, Jay, et al.. (2009). PHP54 EVALUATING DIFFERENCES IN DRUG REIMBURSEMENT BETWEEN MAIL-ORDER AND COMMUNITY PHARMACY. Value in Health. 12(3). A88–A88. 1 indexed citations
15.
Seoane‐Vazquez, Enrique, et al.. (2009). Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.. PubMed. 64(1). 171–81. 2 indexed citations
16.
Seoane‐Vazquez, Enrique, Rosa Rodríguez-Monguió, Sheryl L. Szeinbach, & Jay Visaria. (2008). Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases. 3(1). 33–33. 87 indexed citations
17.
Seoane‐Vazquez, Enrique, et al.. (2007). Endoscopy-related infections and toxic reactions: an international comparison. Endoscopy. 39(8). 742–778. 30 indexed citations
18.
Rodríguez-Monguió, Rosa, et al.. (2007). PHP9 THE IMPACT OF MAIL ORDER PHARMACY IN DRUG UTILIZATION AND REIMBURSEMENT IN A LARGE RETIREMENT SYSTEM. Value in Health. 10(3). A24–A24. 1 indexed citations
19.
Seoane‐Vazquez, Enrique, Rosa Rodríguez-Monguió, Jay Visaria, & Angeline M. Carlson. (2006). Exogenous endoscopy-related infections, pseudo-infections, and toxic reactions: clinical and economic burden. Current Medical Research and Opinion. 22(10). 2007–2021. 33 indexed citations
20.
Seoane‐Vazquez, Enrique, et al.. (2006). PGI11 ECONOMIC BURDEN OF ENDOSCOPY-RELATED INFECTIONS, PSEUDO-INFECTIONS AND TOXIC REACTIONS. Value in Health. 9(3). A46–A46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aliya Jiwani Breakdown of academic impact, for papers by Amanda M. Farr Breakdown of academic impact, for papers by L. Lévy-Bachelot Breakdown of academic impact, for papers by Sohee Park Breakdown of academic impact, for papers by Caterina Bianca Neve Aurora Bianchi Breakdown of academic impact, for papers by Anthony S. Gunnell Breakdown of academic impact, for papers by Kari S. Lankinen Breakdown of academic impact, for papers by A. Cohen Breakdown of academic impact, for papers by Vasileios Sioulas Breakdown of academic impact, for papers by Marleen E. Jansen
Rankless by CCL
2026